|Mr. Haruo Naito||CEO, Representative Corp. Officer & Director||N/A||N/A||1947|
|Mr. Gary Hendler||Sr. VP & Pres of EMEA Region||N/A||N/A||1966|
|Dr. Lynn D. Kramer||VP and Chief Clinical Officer & Chief Medical Officer - Neurology Bus. Group||N/A||N/A||1950|
|Ms. Shaji Procida||VP and Pres & COO of Eisai Inc.||N/A||N/A||1971|
|Mr. Nadeem Sarwar||Pres||N/A||N/A||N/A|
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia. It also offers Aricept for the treatment of Alzheimer's disease/dementia with Lewy bodies worldwide; and BELVIQ, an antiobesity agent in the United States. In addition, it develops Halaven, an anticancer agent in the oncology area for use in the treatment of breast cancer in approximately 65 countries and also for use in the treatment of malignant soft tissue sarcoma in 50 countries; and Lenvima, an anticancer agent for use in the treatment of thyroid cancer in Japan, the United States, Europe, and Asia. Further, the company has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in the United States and Europe. It has a strategic collaboration with Merck & Co., Inc. for Lenvima in the oncology and dementia fields; and a collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop the combination therapy of Lenvima and Opdivo for the treatment of hepatocellular carcinoma. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Eisai Co., Ltd.’s ISS Governance QualityScore as of June 25, 2019 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 10; Compensation: 3.